Alexander Pan
YOU?
Author Swipe
View article: Infectious endocarditis on percutaneous aortic valve prosthesis: comparison with surgical bioprostheses
Infectious endocarditis on percutaneous aortic valve prosthesis: comparison with surgical bioprostheses Open
Introduction and objectives: Infective endocarditis (IE) is a rare but serious complication in patients with aortic valve stenosis undergoing transcatheter aortic valve implantation (TAVI). The spread of this technique to lower risk patien…
View article: Supplementary Figure S4 from Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics
Supplementary Figure S4 from Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics Open
Supplemental Figure 4. 4-mer end motifs across F-profiles. Comprehensive view of the distribution and prevalence of each possible 4-mer end motif within each of the six distinct F-profiles derived from non-negative matrix factorization (NM…
View article: Supplementary Figure S3 from Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics
Supplementary Figure S3 from Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics Open
Supplemental Figure 3. Number of NMF components versus AUC. Performance (AUC) of NMF models in OVO comparisons is plotted against the number n components (Methods) used. The number of components approaches the AUC’s asymptote in each OVO a…
View article: Supplementary Figure S2 from Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics
Supplementary Figure S2 from Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics Open
Supplemental Figure 2. Diminishing improvements in accuracy with deeper sequencing. MPNST samples sequenced to ∼25x were downsampled in five iterations per goal coverage (Methods). Size selected, copy number derived tumor fraction variabil…
View article: Supplementary Figure S1 from Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics
Supplementary Figure S1 from Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics Open
Supplemental Figure 1. Attributes of atypical neurofibroma samples. Histologic characteristics and, when available, TSO500 clinical sequencing results for paired tissue corresponding with AN cell-free DNA.
View article: Data from Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics
Data from Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics Open
Purpose:Early detection of neurofibromatosis type 1 (NF1)–associated peripheral nerve sheath tumors (PNST) informs clinical decision-making, enabling early definitive treatment and potentially averting deadly outcomes. In this study, we de…
View article: Supplementary Tables S1-S3 from Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics
Supplementary Tables S1-S3 from Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics Open
Supplemental Table 1. Participant characteristics. Supplemental Table 2. MPNST patient characteristics. Supplemental Table 3. Details of all sequencing libraries in this study.
View article: Supplementary Dataset S1 from Phase I trial of ganitumab plus dasatinib to cotarget the insulin-like growth factor 1 receptor and Src family kinase YES in rhabdomyosarcoma
Supplementary Dataset S1 from Phase I trial of ganitumab plus dasatinib to cotarget the insulin-like growth factor 1 receptor and Src family kinase YES in rhabdomyosarcoma Open
Fusion-positive RMS enhancer sites; Universal DNAase-hypersensitivity sites; YES1 and IGF1R region sets
View article: Supplementary Table S3 from Phase I trial of ganitumab plus dasatinib to cotarget the insulin-like growth factor 1 receptor and Src family kinase YES in rhabdomyosarcoma
Supplementary Table S3 from Phase I trial of ganitumab plus dasatinib to cotarget the insulin-like growth factor 1 receptor and Src family kinase YES in rhabdomyosarcoma Open
Adverse events possibly probably or definitely related to dasatinib across all 28 cycles (maximum grade per patient)
View article: Supplementary Table S4 from Phase I trial of ganitumab plus dasatinib to cotarget the insulin-like growth factor 1 receptor and Src family kinase YES in rhabdomyosarcoma
Supplementary Table S4 from Phase I trial of ganitumab plus dasatinib to cotarget the insulin-like growth factor 1 receptor and Src family kinase YES in rhabdomyosarcoma Open
Tumor fractions from plasma cfDNA.
View article: Supplementary Appendix S1 from Phase I trial of ganitumab plus dasatinib to cotarget the insulin-like growth factor 1 receptor and Src family kinase YES in rhabdomyosarcoma
Supplementary Appendix S1 from Phase I trial of ganitumab plus dasatinib to cotarget the insulin-like growth factor 1 receptor and Src family kinase YES in rhabdomyosarcoma Open
Supplemental Protocol Information. A: Study Eligibility; B: Dasatinib dosing nomogram; C: Dasatinib dose modifications
View article: Supplementary Table S5 from Phase I trial of ganitumab plus dasatinib to cotarget the insulin-like growth factor 1 receptor and Src family kinase YES in rhabdomyosarcoma
Supplementary Table S5 from Phase I trial of ganitumab plus dasatinib to cotarget the insulin-like growth factor 1 receptor and Src family kinase YES in rhabdomyosarcoma Open
Summary statistics for nucleosome footprints at YES1 and IGF1R regulatory motifs
View article: Supplementary Table S1 from Phase I trial of ganitumab plus dasatinib to cotarget the insulin-like growth factor 1 receptor and Src family kinase YES in rhabdomyosarcoma
Supplementary Table S1 from Phase I trial of ganitumab plus dasatinib to cotarget the insulin-like growth factor 1 receptor and Src family kinase YES in rhabdomyosarcoma Open
Representativeness of Study Participants
View article: Supplementary Table S4 from Phase I trial of ganitumab plus dasatinib to cotarget the insulin-like growth factor 1 receptor and Src family kinase YES in rhabdomyosarcoma
Supplementary Table S4 from Phase I trial of ganitumab plus dasatinib to cotarget the insulin-like growth factor 1 receptor and Src family kinase YES in rhabdomyosarcoma Open
Tumor fractions from plasma cfDNA.
View article: Supplementary Figure S1 from Phase I trial of ganitumab plus dasatinib to cotarget the insulin-like growth factor 1 receptor and Src family kinase YES in rhabdomyosarcoma
Supplementary Figure S1 from Phase I trial of ganitumab plus dasatinib to cotarget the insulin-like growth factor 1 receptor and Src family kinase YES in rhabdomyosarcoma Open
Progression-free survival for full cohort of patients (A) and by dose level (B).
View article: Supplementary Appendix S1 from Phase I trial of ganitumab plus dasatinib to cotarget the insulin-like growth factor 1 receptor and Src family kinase YES in rhabdomyosarcoma
Supplementary Appendix S1 from Phase I trial of ganitumab plus dasatinib to cotarget the insulin-like growth factor 1 receptor and Src family kinase YES in rhabdomyosarcoma Open
Supplemental Protocol Information. A: Study Eligibility; B: Dasatinib dosing nomogram; C: Dasatinib dose modifications
View article: Supplementary Figure S1 from Phase I trial of ganitumab plus dasatinib to cotarget the insulin-like growth factor 1 receptor and Src family kinase YES in rhabdomyosarcoma
Supplementary Figure S1 from Phase I trial of ganitumab plus dasatinib to cotarget the insulin-like growth factor 1 receptor and Src family kinase YES in rhabdomyosarcoma Open
Progression-free survival for full cohort of patients (A) and by dose level (B).
View article: Supplementary Figure S2 from Phase I trial of ganitumab plus dasatinib to cotarget the insulin-like growth factor 1 receptor and Src family kinase YES in rhabdomyosarcoma
Supplementary Figure S2 from Phase I trial of ganitumab plus dasatinib to cotarget the insulin-like growth factor 1 receptor and Src family kinase YES in rhabdomyosarcoma Open
Serial samples demonstrate recurrent loci with copy number alterations for each patient.
View article: Supplementary Table S5 from Phase I trial of ganitumab plus dasatinib to cotarget the insulin-like growth factor 1 receptor and Src family kinase YES in rhabdomyosarcoma
Supplementary Table S5 from Phase I trial of ganitumab plus dasatinib to cotarget the insulin-like growth factor 1 receptor and Src family kinase YES in rhabdomyosarcoma Open
Summary statistics for nucleosome footprints at YES1 and IGF1R regulatory motifs
View article: Supplementary Figure S2 from Phase I trial of ganitumab plus dasatinib to cotarget the insulin-like growth factor 1 receptor and Src family kinase YES in rhabdomyosarcoma
Supplementary Figure S2 from Phase I trial of ganitumab plus dasatinib to cotarget the insulin-like growth factor 1 receptor and Src family kinase YES in rhabdomyosarcoma Open
Serial samples demonstrate recurrent loci with copy number alterations for each patient.
View article: Supplementary Table S2 from Phase I trial of ganitumab plus dasatinib to cotarget the insulin-like growth factor 1 receptor and Src family kinase YES in rhabdomyosarcoma
Supplementary Table S2 from Phase I trial of ganitumab plus dasatinib to cotarget the insulin-like growth factor 1 receptor and Src family kinase YES in rhabdomyosarcoma Open
Adverse events possibly, probably, or definitely related to ganitumab across all 28 cycles (maximum grade per patient)
View article: Data from Phase I trial of ganitumab plus dasatinib to cotarget the insulin-like growth factor 1 receptor and Src family kinase YES in rhabdomyosarcoma
Data from Phase I trial of ganitumab plus dasatinib to cotarget the insulin-like growth factor 1 receptor and Src family kinase YES in rhabdomyosarcoma Open
Purpose: Antibodies against IGF-1R have shown meaningful but transient tumor responses in patients with rhabdomyosarcoma (RMS). The SRC family member YES has been shown to mediate IGF-1R antibody acquired resistance, and cotargeting IGF-1R…
View article: Supplementary Table S1 from Phase I trial of ganitumab plus dasatinib to cotarget the insulin-like growth factor 1 receptor and Src family kinase YES in rhabdomyosarcoma
Supplementary Table S1 from Phase I trial of ganitumab plus dasatinib to cotarget the insulin-like growth factor 1 receptor and Src family kinase YES in rhabdomyosarcoma Open
Representativeness of Study Participants
View article: Supplementary Table S3 from Phase I trial of ganitumab plus dasatinib to cotarget the insulin-like growth factor 1 receptor and Src family kinase YES in rhabdomyosarcoma
Supplementary Table S3 from Phase I trial of ganitumab plus dasatinib to cotarget the insulin-like growth factor 1 receptor and Src family kinase YES in rhabdomyosarcoma Open
Adverse events possibly probably or definitely related to dasatinib across all 28 cycles (maximum grade per patient)
View article: Supplementary Dataset S1 from Phase I trial of ganitumab plus dasatinib to cotarget the insulin-like growth factor 1 receptor and Src family kinase YES in rhabdomyosarcoma
Supplementary Dataset S1 from Phase I trial of ganitumab plus dasatinib to cotarget the insulin-like growth factor 1 receptor and Src family kinase YES in rhabdomyosarcoma Open
Fusion-positive RMS enhancer sites; Universal DNAase-hypersensitivity sites; YES1 and IGF1R region sets
View article: Supplementary Table S2 from Phase I trial of ganitumab plus dasatinib to cotarget the insulin-like growth factor 1 receptor and Src family kinase YES in rhabdomyosarcoma
Supplementary Table S2 from Phase I trial of ganitumab plus dasatinib to cotarget the insulin-like growth factor 1 receptor and Src family kinase YES in rhabdomyosarcoma Open
Adverse events possibly, probably, or definitely related to ganitumab across all 28 cycles (maximum grade per patient)
View article: Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics
Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics Open
Purpose: Early detection of neurofibromatosis type 1 (NF1)–associated peripheral nerve sheath tumors (PNST) informs clinical decision-making, enabling early definitive treatment and potentially averting deadly outcomes. In this study, we d…
View article: Early detection of malignant and pre-malignant peripheral nerve tumors using cell-free DNA fragmentomics
Early detection of malignant and pre-malignant peripheral nerve tumors using cell-free DNA fragmentomics Open
Early detection of neurofibromatosis type 1 (NF1) associated peripheral nerve sheath tumors (PNST) informs clinical decision-making, potentially averting deadly outcomes. Here, we describe a cell-free DNA (cfDNA) fragmentomic approach whic…
View article: Data from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
Data from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma Open
Purpose:Antibodies against insulin-like growth factor (IGF) type 1 receptor have shown meaningful but transient tumor responses in patients with rhabdomyosarcoma (RMS). The SRC family member YES has been shown to mediate IGF type 1 recepto…
View article: Supplementary Appendix S1 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
Supplementary Appendix S1 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma Open
Supplemental Protocol Information. A: Study Eligibility; B: Dasatinib dosing nomogram; C: Dasatinib dose modifications